Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer

The prognosis of most thyroid cancer patients is excellent, but for those with advanced or metastatic thyroid cancer, effective treatments are still lacking. Chimeric antigen receptor (CAR) T-cell therapy has gained remarkable achievements in hematologic malignancy but shown limited efficacy in soli...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Jing, Li, Deyu, Liu, Xingchen, Hei, Hu, Sun, Baoxi, Zhou, Dongmin, Zhou, Keshu, Song, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494903/
https://www.ncbi.nlm.nih.gov/pubmed/36138444
http://dx.doi.org/10.1186/s40164-022-00311-z
_version_ 1784793892318609408
author Ding, Jing
Li, Deyu
Liu, Xingchen
Hei, Hu
Sun, Baoxi
Zhou, Dongmin
Zhou, Keshu
Song, Yongping
author_facet Ding, Jing
Li, Deyu
Liu, Xingchen
Hei, Hu
Sun, Baoxi
Zhou, Dongmin
Zhou, Keshu
Song, Yongping
author_sort Ding, Jing
collection PubMed
description The prognosis of most thyroid cancer patients is excellent, but for those with advanced or metastatic thyroid cancer, effective treatments are still lacking. Chimeric antigen receptor (CAR) T-cell therapy has gained remarkable achievements in hematologic malignancy but shown limited efficacy in solid tumors. In this report, we showed a relapsed and refractory thyroid cancer patient treated with TSHR + CD19 CAR-T, a combination of two 2nd generation CAR-T molecules targeting both TSHR and CD19. This patient finally achieved partial remission at 3 months and was tolerate well to the regimen. Our study suggested that the CAR-T therapy could be a feasible way in treating relapsed and refractory thyroid cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-022-00311-z.
format Online
Article
Text
id pubmed-9494903
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94949032022-09-23 Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer Ding, Jing Li, Deyu Liu, Xingchen Hei, Hu Sun, Baoxi Zhou, Dongmin Zhou, Keshu Song, Yongping Exp Hematol Oncol Correspondence The prognosis of most thyroid cancer patients is excellent, but for those with advanced or metastatic thyroid cancer, effective treatments are still lacking. Chimeric antigen receptor (CAR) T-cell therapy has gained remarkable achievements in hematologic malignancy but shown limited efficacy in solid tumors. In this report, we showed a relapsed and refractory thyroid cancer patient treated with TSHR + CD19 CAR-T, a combination of two 2nd generation CAR-T molecules targeting both TSHR and CD19. This patient finally achieved partial remission at 3 months and was tolerate well to the regimen. Our study suggested that the CAR-T therapy could be a feasible way in treating relapsed and refractory thyroid cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-022-00311-z. BioMed Central 2022-09-22 /pmc/articles/PMC9494903/ /pubmed/36138444 http://dx.doi.org/10.1186/s40164-022-00311-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Ding, Jing
Li, Deyu
Liu, Xingchen
Hei, Hu
Sun, Baoxi
Zhou, Dongmin
Zhou, Keshu
Song, Yongping
Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
title Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
title_full Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
title_fullStr Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
title_full_unstemmed Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
title_short Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
title_sort chimeric antigen receptor t-cell therapy for relapsed and refractory thyroid cancer
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494903/
https://www.ncbi.nlm.nih.gov/pubmed/36138444
http://dx.doi.org/10.1186/s40164-022-00311-z
work_keys_str_mv AT dingjing chimericantigenreceptortcelltherapyforrelapsedandrefractorythyroidcancer
AT lideyu chimericantigenreceptortcelltherapyforrelapsedandrefractorythyroidcancer
AT liuxingchen chimericantigenreceptortcelltherapyforrelapsedandrefractorythyroidcancer
AT heihu chimericantigenreceptortcelltherapyforrelapsedandrefractorythyroidcancer
AT sunbaoxi chimericantigenreceptortcelltherapyforrelapsedandrefractorythyroidcancer
AT zhoudongmin chimericantigenreceptortcelltherapyforrelapsedandrefractorythyroidcancer
AT zhoukeshu chimericantigenreceptortcelltherapyforrelapsedandrefractorythyroidcancer
AT songyongping chimericantigenreceptortcelltherapyforrelapsedandrefractorythyroidcancer

Ejemplares similares